An adaptive power prior for sequential clinical trials – Application to bridging studies
暂无分享,去创建一个
Satoshi Morita | Moreno Ursino | Sarah Zohar | S. Morita | S. Zohar | M. Ursino | Adrien Ollier | Adrien Ollier
[1] Ying Yuan,et al. Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials , 2009 .
[2] Kit C B Roes,et al. Dynamic borrowing through empirical power priors that control type I error , 2018, Biometrics.
[3] P. Müller,et al. Determining the Effective Sample Size of a Parametric Prior , 2008, Biometrics.
[4] Adrian E. Raftery,et al. Bayesian model averaging: a tutorial (with comments by M. Clyde, David Draper and E. I. George, and a rejoinder by the authors , 1999 .
[5] S J Pocock,et al. The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.
[6] Joseph G Ibrahim,et al. The power prior: theory and applications , 2015, Statistics in medicine.
[7] Bradley P Carlin,et al. Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. , 2012, Bayesian analysis.
[8] Adam Himes,et al. Incorporation of stochastic engineering models as prior information in Bayesian medical device trials , 2017, Journal of biopharmaceutical statistics.
[9] Tim Friede,et al. Dynamically borrowing strength from another study through shrinkage estimation , 2018, Statistical methods in medical research.
[10] Sarah Zohar,et al. An approach to meta‐analysis of dose‐finding studies , 2011, Statistics in medicine.
[11] Joseph G Ibrahim,et al. A practical Bayesian adaptive design incorporating data from historical controls , 2018, Statistics in medicine.
[12] S. Morita,et al. Incorporating Historical Data in Bayesian Phase I Trial Design: The Caucasian-to-Asian Toxicity Tolerability Problem , 2015, Therapeutic innovation & regulatory science.
[13] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[14] B. Reigner,et al. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer , 2003, Cancer Chemotherapy and Pharmacology.
[15] L Zhang,et al. The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies , 2008, Clinical pharmacology and therapeutics.
[16] Satoshi Morita,et al. Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies , 2016, Statistical methods in medical research.
[17] Ying Yuan,et al. Bridging continual reassessment method for phase I clinical trials in different ethnic populations , 2015, Statistics in medicine.
[18] Leonhard Held,et al. Adaptive power priors with empirical Bayes for clinical trials , 2017, Pharmaceutical statistics.
[19] Anthony O'Hagan,et al. Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.
[20] Ying Kuen Cheung,et al. Dose Finding by the Continual Reassessment Method , 2011 .
[21] Bradley P Carlin,et al. Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials , 2011, Biometrics.
[22] Sarah Zohar,et al. Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study , 2013, Clinical trials.
[23] Yvette van Norden,et al. Including historical data in the analysis of clinical trials: Is it worth the effort? , 2017, Statistical methods in medical research.
[24] Satoshi Morita,et al. Prior Effective Sample Size in Conditionally Independent Hierarchical Models. , 2012, Bayesian analysis.
[25] Dario Gregori,et al. Planning a Bayesian early‐phase phase I/II study for human vaccines in HER2 carcinomas , 2011, Pharmaceutical statistics.
[26] J. Ibrahim,et al. Power prior distributions for regression models , 2000 .
[27] H. Maeda,et al. Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries , 2014, Investigational New Drugs.
[28] Alexia Iasonos,et al. Bridging Solutions in Dose-Finding Problems , 2014, Statistics in biopharmaceutical research.
[29] G. Liu. A dynamic power prior for borrowing historical data in noninferiority trials with binary endpoint , 2018, Pharmaceutical statistics.
[30] J. Bernardo. The Concept of Exchangeability and its Applications , 2001 .
[31] Ying Yuan,et al. A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials. , 2017, Journal of the Royal Statistical Society. Series C, Applied statistics.
[32] Satoshi Morita,et al. Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics , 2010, Statistics in biosciences.
[33] Chikayuki Naito,et al. Ethnic Factors in the Acceptability of Foreign Clinical Data , 1998 .
[34] Michael Branson,et al. A note on the power prior , 2009, Statistics in medicine.